Unicycive Therapeutics, Inc.

Our development programs are focused on two kidney diseases with large unmet medical needs. We are developing Renazorb as a potent and selective second-generation phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. We are also developing UNI-494, a patented pro-drug of a repurposed marketed agent with a target of improved safety and pharmacokinetics, for the treatment of patients with acute kidney injury.

Nasdaq: UNCY
IR Website: https://ir.unicycive.com/
Headquarters: Los Altos, CA

Content provided by Unicycive on 2-25-22.


The Unicycive Therapeutics management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.


Investor Presentation

Management Overview

Risks & Disclosures